An Open Label Phase II Study Combining Nivolumab and Celecoxib in Patients With Advanced Cold Solid Tumors (NICE-COMBO)
NICE-COMBO: An Open Label Phase II Study Combining Nivolumab and Celecoxib in Patients With Advanced Cold Solid Tumors
Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Listed as NCT03864575, this PHASE2 trial focuses on Metastatic Cancer and remains ongoing. Sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain, it has been updated 7 times since 2019, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Oct 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Not Yet Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE2
▶ Show 2 earlier versions
-
Aug 2019 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2019 — Aug 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
For direct contact, visit the study record on ClinicalTrials.gov .